Table 3.
Univariate and multivariate analysis of predictors of PFS in the mCRC cohort.
| PFS | Univariate Cox Regression | Multivariable Cox Regression | ||
|---|---|---|---|---|
| HR (95%CI) | p-Value | HR (95%CI) | p-Value | |
| Gene stratification | ||||
| PRG | 1.00 | 1.00 | ||
| AGG | 1.91 (1.16–3.15) | 0.011 | 1.84 (1.03–3.28) | 0.039 |
| NMG | 2.63 (1.26–5.47) | 0.010 | 1.81 (0.65–5.01) | 0.253 |
| Age (>65y vs. ≤65y) | 1.30 (0.74–2.29) | 0.364 | ||
| Gender (F vs. M) | 2.02 (1.11–3.67) | 0.021 | ||
| Grading (G1 vs. G2 vs. G3) | 1.05 (0.65–1.70) | 0.837 | ||
| Primay tumor location (RCT vs. RC vs. LC) | 0.78 (0.54–1.13) | 0.192 | ||
| Adjuvant therapy (Y vs. N) | 1.38 (0.83−2.28) | 0.210 | ||
| Metastatic site (liver and/or other vs. liver) | 1.57 (0.92–2.68) | 0.100 | ||
| ECOG PS (≥2 vs. 0–1) | 0.22 (0.04–1.17) | 0.077 | ||
| Surgery for primiry tumor (Y vs. N) | 0.66 (0.18–2.44) | 0.537 | ||
| Therapy (CHT vs. CHT+antiVEGF vs. CHT+antiEGFR) | 0.64 (0.30–1.36) | 0.251 | ||
PFS = progression-free survival; HR = hazard ratio; CI = confidence interval; F = Female; M = Male; RCT=rectum, RC= right colon; LC=left colon; CHT=chemotherapy.